Week Ending October 4, 2021

Cancer Without Chemotherapy: ‘A Totally Different World’
“A growing number of cancer patients, especially those with breast and lung cancers, are being spared the dreaded treatment in favor of other options.”

Some Areas Lag Behind in Decreasing Lung Cancer Death Rates
“Despite a decrease in lung cancer rates across the country, significant differences in disease rates and outcomes remain at the state level, according to a presentation at the 2021 World Conference on Lung Cancer.”

Did USPSTF’s Change in Lung Cancer Screening Recs Address Inequity?
“The latest lung cancer screening guidelines from the U.S. Preventive Services Task Force (USPSTF) might have lowered eligibility thresholds for screening but they don’t appear to have addressed equity concerns.”

Taletrectinib May Show Promise in ROS1+ Non–Small Cell Lung Cancer
“Taletrectinib (AB-106) demonstrated promising interim results in patients with ROS1-positive non–small cell lung cancer (NSCLC), according to data from the phase 2 TRUST trial (NCT04395677) that were presented at the 2021 Chinese Society of Clinical Oncology Annual Meeting.”

Lung Cancer Mutation Consortium Begins Study Screening Patients for Neoadjuvant Therapy Biomarkers
“The Lung Cancer Mutation Consortium said on Tuesday it has begun an umbrella trial, called LCMC4 Evaluation of Actionable Drivers in Early Stage Lung Cancer, or LEADER, in which it will screen early-stage lung cancer patients for driver mutations that can be targeted with neoadjuvant therapy.”

Rovalpituzumab Tesirine Falls Flat in Small Cell Lung Cancer
“Rovalpituzumab tesirine (Rova-T) failed to show an efficacy or safety benefit as a frontline, maintenance, and second-line treatment for patients with advanced small cell lung cancer (SCLC), warranting its discontinued development, according to findings from 4 independent studies published in the Journal of Thoracic Oncology”

What is the doubling time for small cell lung cancer?
“Small cell lung cancer (SCLC) is an aggressive form of lung cancer that has a short doubling time. The term “doubling time” refers to the amount of time it takes for a cell or tumor to double in size.”

Roundtable Discussion: Treatment Goals for RET-Mutated Lung Cancer
“During a Targeted OncologyTM Case-Based Roundtable event, Nicholas J. Vogelzang, MD, chairman, Medical Oncology at the Comprehensive Cancer Centers and clinical professor of Medicine at the University of Nevada, Reno School of Medicine in Las Vegas, NV,, discussed the case of a 59-year-old patient with RET-mutated lung cancer. Vogelzang was joined in his discussion by 9 peers.”

Navigating Emotional Response to a Lung Cancer Diagnosis